Pharmaceuticals News and Research

RSS

Lonza nominates Juan Andres and Eric Drapé as independent Board Members

Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at the Lonza Group Annual General Meeting (AGM) in May 2025.

From Lonza 20 Sep 2024

FORT-2 trial shows promising results for bladder cancer immunotherapy combination

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.

19 Sep 2024

Study highlights disparities in stroke burden across regions

Although stroke is highly preventable and treatable, there has been a rapid rise in the global stroke burden between 1990 and 2021, due to both population growth and the rise of aging populations worldwide, as well as a substantial increase in people's exposure to environmental and behavioral risk factors.

19 Sep 2024

New biomarkers offer hope for early detection and prevention of Alzheimer's

The failure to diagnose Alzheimer's disease, the most common form of dementia in the elderly, at an early stage of molecular pathology is considered a major reason why treatments fail in clinical trials. Previous research to molecularly diagnose Alzheimer's disease yielded "A/T/N" central biomarkers based on the measurements of proteins, β-amyloid ("A") and tau ("T"), and "N" encompassing neurodegeneration. A/T/N can be measured in brain tissue, by in vivo brain imaging techniques, and by analysis of cerebrospinal fluid and plasma.

18 Sep 2024

Antibiotic resistance threatens millions of lives worldwide

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.

18 Sep 2024

Pushing the limits — Pharma characterization with light scattering

Bettersize's upcoming webinar will delve into particle size and zeta potential, showcasing their importance in pharmaceutical development and product quality.

From Bettersize Instruments Ltd. 18 Sep 2024

LabVantage named Global LIMS Company of the year by Frost & Sullivan

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS platforms enabling rapid deployment at reduced costs, today announced it has been awarded the prestigious Company of the Year Award in the Global Laboratory Information Management Systems (LIMS) Industry by Frost & Sullivan.

From LabVantage Solutions 17 Sep 2024

Combination treatment improves symptoms of agitated delirium in end-of-life cancer patients

Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.

16 Sep 2024

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer.

13 Sep 2024

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Liraglutide treatment significantly lowers BMI in obese children aged 6 to <12, but gastrointestinal side effects prompt the need for additional studies.

13 Sep 2024

Research highlights cardiovascular benefits of semaglutide for overweight adults with impaired kidney function

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don't have diabetes, whether or not they also have impaired kidney function, according to new research to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

13 Sep 2024

Study links protein increases to cognitive improvement in Alzheimer's

A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the slowing of cognitive impairment at least as well as the reduction in amyloid plaques.

11 Sep 2024

Study reveals shared and unique molecular markers across multiple forms of dementia

Researchers have for the first time identified degeneration-associated "molecular markers" – observable changes in cells and their gene-regulating networks – that are shared by several forms of dementia that affect different regions of the brain.

11 Sep 2024

New target identified for potential ALS therapy

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that affects motor neurons.

10 Sep 2024

Girls exposed to endocrine-disrupting chemicals may be more likely to start puberty early

Girls exposed to certain endocrine-disrupting chemicals (EDCs) may be more likely to start puberty early, according to new research published in Endocrinology, the flagship basic science journal of the Endocrine Society.

10 Sep 2024

HKUST researchers unveil eco-friendly disinfectant alternative to chloroxylenol

A widely used disinfectant worldwide, chloroxylenol, has been associated with eco-toxicological threats in water environments due to its relatively high chemical stability and massive consumption.

6 Sep 2024

Automata Technologies appoints advisory board of senior health and life sciences industry executives

Automata Technologies, a leading automation company powering automation in the life sciences labs, has appointed its first advisory board, consisting of senior global healthcare and life sciences industry executives.

From Automata 6 Sep 2024

New evidence supports continuous infusion for GI cancers

New research just published online by JNCCN-; Journal of the National Comprehensive Cancer Network finds that for many commonly used treatment regimens targeting metastatic gastrointestinal (GI) cancers, such as FOLFOX, FOLFIRI, or FOLFIRINOX, it is possible to administer 5-FU solely through continuous infusion, minus the bolus (quick-delivery via intravenous push) component, without negatively affecting patient outcomes.

6 Sep 2024

Sports concussions may not be related to long-term cognitive risks for non-professional athletes

Sports-related concussions (SRC) may not be associated with long-term cognitive risks for non-professional athletes, a study led by a UNSW medical researcher suggests.

4 Sep 2024

Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of final data from the RESTORE open-label/switch study, demonstrating that people with narcolepsy prefer once-at-bedtime LUMRYZ versus a twice-nightly immediate-release oxybate treatment option.

From Avadel Pharmaceuticals 4 Sep 2024

1
2
3
4
...
1265
Next

Pharmaceuticals News and Research

Lonza nominates Juan Andres and Eric Drapé as independent Board Members

FORT-2 trial shows promising results for bladder cancer immunotherapy combination

Study highlights disparities in stroke burden across regions

New biomarkers offer hope for early detection and prevention of Alzheimer's

Antibiotic resistance threatens millions of lives worldwide

Pushing the limits — Pharma characterization with light scattering

LabVantage named Global LIMS Company of the year by Frost & Sullivan

Combination treatment improves symptoms of agitated delirium in end-of-life cancer patients

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Research highlights cardiovascular benefits of semaglutide for overweight adults with impaired kidney function

Study links protein increases to cognitive improvement in Alzheimer's

Study reveals shared and unique molecular markers across multiple forms of dementia

New target identified for potential ALS therapy

Girls exposed to endocrine-disrupting chemicals may be more likely to start puberty early

HKUST researchers unveil eco-friendly disinfectant alternative to chloroxylenol

Automata Technologies appoints advisory board of senior health and life sciences industry executives

New evidence supports continuous infusion for GI cancers

Sports concussions may not be related to long-term cognitive risks for non-professional athletes

Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News